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Abstract
A sulfonamide 1-tosyl-1-H-benzo(d)imidazol-2-amine (TBZA) and three new complexes of Co(II),
Cu(II), and Zn(II) have been synthesized. The compounds have been characterized by elemental
analyses, FTIR, 1H, and 13C-NMR spectroscopy. The structure of the TBZA, and its Co(II) and Cu(II)
complexes, was determined by X-ray diffraction methods. TBZA and its Co(II) complex
crystallize in the triclinic P-1 space group, while the Cu(II) complex crystallizes in the monoclinic
P21/c space group. Antifungal activity was screened against eight pathogenic yeasts: Candida
albicans (DMic 972576), Candida krusei (DMic 951705), Candida glabrata (DMic 982882), Candida
tropicalis (DMic 982884), Candida dubliniensis (DMic 93695), Candida guilliermondii (DMic
021150), Cryptococcus neoformans (ATCC 24067), and Cryptococcus gattii (ATCC MYA-4561).
Results on the inhibition of various human (h) CAs, hCA I, II, IV, VII, IX, and XII, and pathogenic
beta and gamma CAs are also reported.
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Introduction
Sulfonamide inhibitors of the metalloenzyme carbonic anhydrase
(CA, EC 4.2.1.1) such as acetazolamide (AZA) have been used
clinically as diuretics, antiglaucoma, or anticonvulsant agents for
long periods1–9, whereas more recent drug design studies have
evidenced other CA inhibitors (CAIs) belonging to the sulfona-
mide/sulfamate/sulfoamide classes as molecules of interest for
developing novel therapies for obesity10,11 and cancer12–15. They
are based on the selective inhibition of CA isozymes involved in
those pathologies. To date, 15 such isoforms have been described
in humans1,16.
Invasive fungal infections constitute an ever-increasing cause
of morbidity and mortality among immunocompromised individ-
uals, those who have undergone intra-abdominal surgery, neo-
nates, and the elderly17. While fluconazole remains an important
agent for the treatment of Candida and other yeasts infections, the
introduction of other triazoles active against yeasts and molds,
such as posaconazole, and voriconazole, or drugs belonging to
other classes, such as echinocandin, anidulafungin, caspofungin,
and micafungin, has increased the options for prophylaxis, and
therapy of many fungal infections18,19.
Another important pathogen in oral health is Porphyromonas
gingivalis, coccobacillus gram-negative, immobile, strictly anaer-
obic, responsible for diseases such as chronic periodontitis. It has
also been identified as a risk factor for lung infections, in
immunocompromised patients, preterm births, and other dis-
eases20. A CA enzyme called PgiCA present in P. gingivalis,
belonging to the gamma CA class, has been investigated for its
inhibition profile with sulfonamides and other compounds21.
Thus, the mechanism of sulfonamides action for inhibiting the
growth and development of strains of this microorganism has been
proposed as a new antiinfective strategy.
In this work, the synthesis of TBZA, a new sulfonamide and
its three metal complexes with Co(II), Cu(II) and Zn(II) is
presented. Furthermore, the crystal structures of TBZA, Co(II),
and Cu(II) complexes are reported, as well as a complete
characterization of the four solid phases. Based on the
biological tests, the possible effectiveness of these new
compounds as antifungal agents is discussed, evaluating whether
the mechanism of action of carbonic anhydrase enzyme is
involved. The antifungal activity of these new compounds was
also assessed ex vivo.
Experimental
Materials
All reagents were supported by Sigma-Aldrich and Merck.
Address for correspondence: Gerardo E. Camı´. E-mail: gecami@
unsl.edu.ar
Synthesis
The sulfonamide synthesis was performed in one stage22 by the
dissolution of 0.5 g (2.624 mmol) of p-toluenesulfonyl chloride,
100 mg (0.82 mmol) of 4-dimethylaminopyridine (4-DMAP) and
0.3 mL (3.57 mmol) of Et3N as catalysts, in 30 mL of dry CH2Cl2
at room temperature and under Ar environment (Figure 1). Once
dissolved, 0.4 g (3 mmol) of 2-aminobenzimidazole was added to
the reaction mixture. The reaction was controlled using TLC, and
when it was complete, the solvent was removed under vacuum,
and then, 1-M HCl was added to remove catalyst and excess
reagents. The white solid obtained was recrystallized from
absolute ethanol, very slowly evaporating the solvent at 15 C
and protecting compound from direct light. A week later,
yellowish transparent needle-like TBZA crystals appeared, and
some of them were selected for structural determination by single
crystal XRD. The yield of the reaction was 85%. The elemental
analysis resulted as follows: C 61.2% (ca. 58.54%), H 5.1% (ca.
4.53%), N 12.8% (ca. 14.63%), S 9.7% (ca. 11.15%), and O 11.2%
(ca. 11.15%). Sulfanilamide was used as reference.
The Cu(II) complex was obtained by dissolving 17.0 mg
(0.1 mmol) of CuCl2.2H2O in 20 mL of absolute ethanol, and
subsequently, 57.4 mg (0.2 mmol) of sulfonamide was added. The
appearance of a dark green color in the final solution was
observed. The Co(II) complex was obtained by dissolving 23.8 mg
(0.1 mmol) of CoCl2.6H2O in 20 mL of absolute ethanol, subse-
quently adding 57.4 mg (0.2 mmol) sulfonamide. A dark blue
color in the final solution was observed. The Zn(II) complex was
obtained by dissolving 15.4 mg (0.1 mmol) of ZnCl2.H2O in
20 mL of absolute ethanol, and then adding 57.4 mg (0.2 mmol) of
sulfonamide. This resulted in a full dissolution, leaving a clear
colorless solution. Mother-waters were filtered to let them
crystallize two weeks, obtaining dark green crystals (in the case
of the Cu(II) complex), prismatic crystals of intense blue color (in
the case of the Co(II) complex), and a white crystalline precipitate
in the case of the Zn(II) complex. Some single crystals of Co(II)
and Cu(II) complexes were selected for single crystal XRD
structural determination. The average yield in the obtaining of the
complexes was 65%. The result of elemental analysis was: C
49.8% (ca. 47.74%), H 4.7% (ca. 3.69%), N 10.2% (ca. 11.93%), S
7.5% (ca. 9.09%), and O 10.1% (ca. 9.09%) in Co(II) complex; C
50.5% (ca. 47.43%), H 5.1% (ca. 3.67%), N 11.2% (ca. 11.86%), S
7.8% (ca. 9.03%), and O 10.7% (ca. 9.03%) in Cu(II) complex; C
48.8% (ca. 47.30%), H 4.6% (ca. 3.66%), N 10.7% (ca. 11.82%), S
8.1% (ca. 9.01%), and O 10.0% (ca. 9.01%) in Zn(II) complex.
Sulfanilamide was used as reference. The difference found in the
corresponding measures for the Cu(II) complex is due to the
incorporation of butane in the crystal structure, located randomly
at holes. Butane was included in the used solvent for their
synthesis (ethanol). The approximate ratio of butane is 2.9% of the
total mass of C, H, and O (Table 1).
Methods
The measurements were performed on an Oxford Xcalibur, Eos,
Gemini CCD diffractometer with graphite-monochromated CuKa
(¼ 1.54184 A˚) radiation for TBZA and the Cu(II) complex, and
MoKa (l¼ 0.71073 A˚) radiation for the Co(II) complex. The X-
ray diffraction intensities were collected (! scans with y and
k-offsets), integrated and scaled with CrysAlisPro23 suite of
programs. The unit cell parameters were obtained by least-squares
refinement (based on the angular settings for all collected
reflections with intensities larger than seven times the standard
deviation of measurement errors) using CrysAlisPro. Data were
corrected empirically for absorption, employing the multi-scan
method implemented in CrysAlisPro. The structure was solved by
direct methods with SHELXS-97, and the molecular model was
refined by full-matrix least-squares procedure on F2 with SHELXL-
97 of the SHELX package24 within the WinGX program25.
Except for amide hydrogen atoms, which were positioned from
the Fourier difference map, all H-atoms were positioned on
stereo-chemical basis, and refined with the riding model. The
methyl H-atoms were refined as rigid groups allowed to rotate
around their corresponding CC bond such as to maximize the
sum of the observed residual electron density at their calculated
positions. The structural analysis was performed using the
SHELX package24, PLATON26, and Mercury27, available within
the WinGX program.
The experimental XRPD patterns were obtained on a diffract-
ometer Rigaku D-MAX-IIIC with Cu Ka (¼ 1.5418 A˚) radi-
ation. The data were collected over a range of 10–40 (2) with a
step of 2; the effective counting time was 5 s per step.
The elemental analyses (C, H, N, S) were carried out with a
Carlo Erba EA 1108 microanalyser belonging to the Instituto de
Figure 1. Synthesis of TBZA and its Co(II), Cu(II), and Zn(II) complexes.
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Quı´mica Fı´sica de Materiales, Medio Ambiente y Energı´a
(INQUIMAE), Universidad de Buenos Aires, Argentina.
Sulfanilamide was used as standard.
Fourier-transformed infrared (FT-IR) spectra were recorded on
a Nicolet Prote´ge´ 460 spectrometer provided with a CsI
beamsplitter in the 4000–250 cm1 range with 32 scans and
spectral resolution of 4 cm1, using KBr pellet technique.
Thermogravimetric (TGA) and differential thermal analysis
(DTA) curves were obtained with a Shimadzu TGA-51 Thermal
Analyzer and DTA-50 Thermal Analyzer, using platinum pans,
flowing air at 50 mL min1 and a heating rate of 10 C min1
from room temperature to 1000 C. The Differential Scan
Calorimeter analyses (DSC) were performed with a Shimadzu
DSC-60, using aluminum pans, flowing air at 50 mL min1, and a
heating rate of 10 C min1 from room temperature to 600 C.
To confirm melt or crystalline phase changes, a Leitz Westlar
heating microscope stage was used.
The 1H and 13C-NMR were obtained by a NMR Bruker
Avance 200 MHz spectrometer with a BBI 200 MHz S1 5-mm
probe with gradient in z axis.
Computation
The experimental geometries (i.e. XRD and XRPD) obtained for
the TBZA complexes (TBZA-M(II)) were characterized at the
DFT level of theory by using the B3LYP exchange-correlation
functional. B3LYP is a popular density functional of broad
application with a good performance for weak interaction
calculation28–30. The Stuttgart/Dresden electron core potential
method SDD (ECP) basis set was selected for Co(II), Cu(II), and
Zn(II) atoms, while the 6–311G + (2d,p) basis set was used for all
other atoms.
The geometries of the complexes were fully optimized with no
symmetry constraint and tight convergence criteria, followed by
normal vibrational frequency calculations using the same method
and basis set in order to characterize the stationary points as
minima (no imaginary frequencies), and to obtain their zero-point
vibrational energies. All calculations were carried out with the
Gaussian 09 package31.
In order to characterize the nature and strength of the TBZA-
M(II) formation, QTAIM32,33 analyses was done with the
wave function obtained by single-point calculations using a
larger 6–311G + (2d,p):Def2-QZVP basis sets.
By the QTAIM analysis, the nature and strength of atomic
interactions were studied and classified34. This was carried out by
analyzing the topological properties of the ab initio wave function
according to the Bader’s theory32,33. In brief by the QTAIM
theory, the molecular wave function can be partitioned into
atomic basins. Therefore, the strength of the interactions between
atoms trough the analysis of local properties at the bonding
critical points (BCPs) can be identified and characterized. The
QTAIM analysis was carried out with the AIMPAC suite of
programs35–37.
Microorganisms
For the antifungal activity study, the following yeasts of clinical
relevance were assayed; Candida albicans (DMic 972576),
Candida krusei (DMic 951705), Candida glabrata (DMic
982882), Candida tropicalis (DMic 982884), Candida dubliniensis
Table 1. Crystal data and structure refinement for TBZA (1) and its Cu(II) (2) and Co(II) (3) complexes.
Complex 1 2 3
Empirical formula C28H26N6O4S2 C30H31Cl2CuN6O4S2 C28H26Cl2CoN6O4S2
Formula weight 574.67 738.17 704.50
T (K) 297(2) 297(2) 297(2)
Wavelength (A˚) 1.54184 1.54184 0.71073
Crystal system Triclinic Triclinic Monoclinic
Space group P-1 P-1 P21/c
Unit cell (A˚, )
a 9.7806(6) 11.3456(6) 9.9125(4)
b 10.3229(6) 12.5730(6) 15.9355(7)
c 14.8434(7) 12.6348(6) 19.4059(7)
 80.942(4) 68.044(5) 90.0
 71.444(5) 85.608(4) 92.188(4)
 86.248(4) 71.760(4) 90.0
V (A˚3) 1402.8(1) 1585.94(15) 3063.1(2)
Z 2 2 4
calc (gcm3) 1.360 1.546 1.528
 (mm1) 2.1 4.1 0.916
F(000) 600 760 1444
Crystal size (mm) 0.478 0.207 0.158 0.077 0.169 0.290 0.274 0.183 0.143
-range 3.174 to 74.027 3.984 to 73.438 2.995 to 29.378
Index ranges
10  h 11 14  h 13 12  h 13
12  k 12 15  k 14 21  k 11
18  l 17 15  l 15 26  l 25
Collected 9366 11 933 15 170
Unique 5556 (Rint¼ 0.0231) 6261 (Rint¼ 0.0255) 6981 (Rint¼ 0.0345)
Completeness 99.9% (¼ 67.684) 100.0% (¼ 67.684) 99.8%(¼25.242)
Observed [I42s(I)] 4709 5178 4811
Absorption correction Semi-empirical from equivalents
Tmax/Tmin 1.00000/0.83686 1.00000/0.77619 1.00000/0.96054
Data/restraints/parameters 5556/0/364 6261/1/409 6981/5/406
Goodness-of-fit on F2 1.077 1.091 1.049
R1/wR2 [I42s(I)] 0.0408/0.1200 0.0424/0.1163 0.0480/0.0962
R1/wR2 (all data) 0.0486/0.1273 0.0521/0.1259 0.0838/0.1122
Extinction coefficient 0.0116(6) – –
Dmax/Dmin (e.A˚
3) 0.243/0.299 0.382/0.427 0.357/0.390
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(DMic 93695), Candida guilliermondii (DMic 021150),
Cryptococcus neoformans (ATCC 24067), and Cryptococcus gattii
(ATCC MYA-4561). These yeasts were grown on potato dextrose
agar (PDA) at 37 C for 48–72 h. The isolates were maintained on
PDA at 4 C for further studies. The yeast strains were provided by
the Department of Mycology of the National Institute of Infectious
Diseases by Dr. Carlos G. Malbra´n, Argentina.
Assessment of the antifungal activity
For the assessment of the antifungal activity, 200mL of yeast
(2.0 106 yeast mL1) of each studied strain was aseptically
inoculated into PDA plates. Cavities of 3 mm were made and were
filled with 50 mL of TBZA and its complexes. The plates were
incubated at 37 C for 48 h. After incubation, the zones of
inhibition were measured. In addition, voriconazole and flucon-
azole were used as positive controls. The assays were performed
in triplicate, and the values were expressed in millimeters.
CA inhibition
An Applied Photophysics stopped-flow instrument was used for
assaying the CA-catalyzed CO2 hydration activity
38. Phenol red
(at 0.2 mM) was used as indicator, working at the absorbance
maximum of 557 nm with 10-mM Hepes (pH 7.4) or TRIS (pH
8.3) as buffers and 0.1-M NaClO4 (for maintaining constant ionic
strength) at 20 C, following the CA-catalyzed CO2 hydration
reaction for a period of 10–100 s (the uncatalyzed reaction needed
around 60–100 s in the assay conditions, whereas the catalyzed
ones were of around 6 – 10 s), as described earlier39–46. The CO2
concentrations ranged from 1.7 to 17 mM for the determination of
the kinetic parameters. The uncatalyzed rates were similarly
determined and subtracted from the total observed rates. Enzyme
concentrations in the assay system range of 10–25 nM for all the
enzymes considered in the present study, which have been obtained
as recombinant proteins, in-house, as reported earlier46–51.
Results and discussion
Sulfonamide characterization
An ORTEP52 plot of the TBZA molecule is shown in Figure 2,
and in Table 1, some significant structural parameters are listed.
Bond intramolecular phenyl ring distances, similar to those found
in Cu(II) and Co(II) complexes, were in the range of 1.364(3) to
1.415(3) A˚, as expected for the resonant bond structure of these
cyclic groups. TBZA crystallized with two independent molecules
in the asymmetry unit, differing from one another in the tosyl and
2-aminobenzimidazole group arrangement (Table 2). In addition,
they are nearly perpendicular; the intramolecular angles between
aromatic rings were 88.86(6) and 86.72(8).
A network of intermolecular H-bonds further stabilized the
structure (Table 3). Two benzimidazole groups related by an
inversion center, which laid over the same plane, are connected by
a double H-bond involving one of the amine hydrogen and the
imidazole nitrogen atoms. Beside, the other amine hydrogen atom
establishes a bifurcated H-bond interaction with sulfonyl oxygen
atoms belonging to the same molecule, and to a symmetry-related
molecule53.
Figure 3 shows the FTIR spectra of the sulfonamide and their
complexes with divalent ions; and Table 4 presents the assign-
ment of most important vibrational modes54. The 2-amino group
(benzimidazole ring) presents an asymmetric stretching at 3467–
3453 cm1 and a symmetrical one at 3317 cm1. Low-intensity
Figure 2. View of the two TBZA showing one
of the independent molecules together with
its symmetry-related by an inversion center.
Displacement ellipsoids are drawn at the 30%
probability level, and the intra and intermo-
lecular H-bonds are shown in dashed line.
Symmetry operations are listed in Table 3.
Table 2. Selected bond lengths (A˚), angles and torsional angles () for
TBZA (1) and its Cu(II) (2) and Co(II) (3) complexes.
1 2 3
Bonds*
N11–M 1.983(2) 2.015(2)
N21–M 1.990(2) 2.023(2)
Cl1–M 2.2154(9) 2.3488(1)
Cl2–M 2.2471(8) 2.2327(10)
Bond angles*
N21–M–N11 98.13(9) 110.19(10)
Cl1–M–N11 101.10(6) 105.55(7)
Cl2–M–N11 129.52(7) 107.43(7)
Cl1–M–N21 132.69(7) 108.88(7)
Cl2–M–N21 98.67(7) 110.00(7)
Cl1–M–Cl2 101.43(4) 114.66(4)
Torsional angles
C14–N13–S111–C114 79.0(2) 61.9(2) 60.4(2)
C24–N23–S211–C214 70.8(2) 91.4(2) 80.5(3)
*M¼Cu1 or Co1.
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wide bands, appearing at 3261 and 3211 cm1, were attributed to
of H-bonds, according to what is observed in the crystal structure.
They involve the azole nitrogen of the benzimidazole ring and the
2-amino group. The angular deformation of 2-amino group was
observed at 1595 cm1. The observed bands at 1664, 1558, 1491,
and 1461 cm1 correspond to different C-N stretching, associated
with angular deformation of the methyl group. Bands appearing at
1372 and 1174 cm1 correspond to the asymmetric and symmet-
ric stretching of the sulfonamide sulfonyl group. The band
appearing at 945 cm1 corresponds to the S-N stretching of the
sulfonamide. The assignment of the rest of the bands is presented
in Table 3.
The 1H-NMR spectrum shows two protons of the 2-amino
group (benzimidazole ring) as a singlet which integrates two
protons, with a chemical shift of 6.9 ppm. The 13C-NMR
spectrum shows the quaternary carbon bound to 2-amino group
presenting a chemical shift of 152.1 ppm. The two quaternary
carbons linking six-and five-membered rings of the benzimida-
zole ring have a chemical shift of 142.0 ppm and 130.5 ppm. The
other carbons of the benzimidazole ring are seen as doublets at
116.6 ppm, 121.5 ppm, 124.8 ppm, and 112.5 ppm; corresponding
protons (located in the same order) are observed at 7.29 ppm (d,
7.7 Hz), 7.21 ppm (td, 7.7 Hz, 1.4 Hz), 7.10 ppm (td, 7.7 Hz, 1.4 Hz),
and 7.73 ppm (d, 7.7 Hz). The quaternary carbons of tosyl group are
seen at 134.5 and 146.1 ppm. The carbon of methyl group is
observed as a quadruplet at 21.6 ppm, and its protons as a singlet at
2.37 ppm. The two carbons which are attached to the quaternary
carbon sulfonyl group are observed as a doublet at 127 ppm and
protons at 7.86 ppm (d, 8.3 Hz). The two carbons below the
quaternary carbon, which is bonded to methyl, are observed as a
doublet at 130.2 ppm and protons at 7.26 ppm (d, 8.3 Hz). To
achieve this assignment, the 1H, HSQC, and HMBC calculations
were performed (see figures in Supplementary Material).
Figure 4(a) shows the sulfonamide thermal diagrams (DTA –
TGA). The compound is stable up to 190 C. There is, then, a first
endothermic process without loss of mass (on set 196.69 C), which
is assigned to the fusion of the sulfonamide. This fact was
confirmed using a microscope with heating plate, noting the merger
between 198 and 200 C. Then, there is an exothermic peak (on set
237.04 C) with a loss of mass of 6.64% (ca. 5.23%) corresponding
to the loss of the terminal methyl of the tosyl group. This is
followed by an endothermic process (on set 349.06 C) with a loss
of mass of 46.52% (ca. 45.99%), due to the decomposition of the 2-
aminobenzimidazole ring. Finally an exothermic process happens
(on set 566.74 C) with a loss of mass of 46.84% (ca. 48.78%); no
waste from calcination is observed (see Figure 5).
Complex characterization
Figures 6 and 7 display ORTEP diagrams for the coordination
of the TBZA ligand around Cu(II) and Co(II) metals.
Table 3. Selected intra and intermolecular hydrogen bonds for TBZA (1) and its Cu(II) (2) and Co(II) (3) complexes (A˚ and ).
D–HA Compound D–H HA DA D–HA
Intramolecular H–bonds
N110–H1AACl1 2 0.76 2.48 3.165(2) 148.9
3 0.85(1) 2.37(2) 3.170(3) 157(3)
N210–H2AACl2 2 0.83 2.46 3.169(3) 143.3
3 0.85(1) 2.39(1) 3.201(3) 161(3)
1 0.86 2.14 2.802(2) 133.5
N110–H1ABO112 2 0.80 2.11 2.768(3) 138.5
3 0.85(3) 2.09(2) 2.724(4) 130(3)
1 0.93 2.49 3.043(3) 118.2
C25–H25O213 2 0.88 2.47 2.978(4) 117.4
3 0.93 2.45 3.014(5) 118.7
1 0.86 2.13 2.788(3) 133.2
N210–H2ABO212 2 0.67 2.34 2.829(4) 131.7
3 0.85(1) 2.11(3) 2.764(4) 133(3)
1 0.93 2.42 2.977(3) 118.5
C15–H15O113 2 0.91 2.56 3.112(4) 119.2
1 0.93 2.49 3.043(3) 118.2
C25–H25O213 2 0.88 2.47 2.978(4) 117.4
3 0.93 2.45 3.014(5) 118.7
Intermolecular H–bonds
N110–H1ABN11i 1 0.86 2.09 2.941(3) 171.2
N210–H2AAN21ii 1 0.86 2.17 3.024(3) 170.9
N210–H2ABO112iii 1 0.86 2.38 2.940(2) 123.2
C115–H115O212iv 2 0.93 2.52 3.398(4) 157.1
C15–H15Cl1v 3 0.93 2.94 3.595(3) 128.9
C219–H219O113vi 3 0.93 2.65 3.384(4) 135.9
C32–H32CCl2vii 2 0.96 2.34 3.069(6) 132.3
Symmetry transformations used to generate equivalent atoms: (i) x+ 2, y+ 1, z; (ii) x, y+ 2, z+ 1; (iii) x 1, y+ 1, z; (iv) x+ 1, y, z; (v)
x 1, y, z; (vi) x, y 1/2, z+ 1/2; (vii) x+ 1, y+ 2, z+ 1.
Figure 3. FTIR spectra of TBZA, Co(II) complex, Cu(II) complex, and
Zn(II) complex.
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Bond distances, bond angles, and some relevant intermolecular
distances are listed in Table 2. In both complexes, metal centers
are tetrahedrally coordinated by two chloride atoms and two azole
nitrogen atoms from the benzimidazole ring. Even though the
Cl1-Co1-Cl2 angle, 114.66(4), is larger than the corresponding
one in Cu(II) complex, 101.43(4), presumably due to a larger
electronic chloride cloud repulsion, the coordination sphere of the
Cu(II) complex has the largest distortion from the regular
tetrahedron.
Similar to the TBZA in solid state, benzimidazole and tosyl
ring groups are located approximately perpendicular to each
other, with angles of 81.50(7) and 86.0(1) in the Cu(II)
complex, and of 83.20(8) and 86.0(1) in the Co(II) complex.
These results could be rationalized taking into account that beside
the intramolecular H-bond established by the 2-amino group of
the benzimidazole ring with the oxygen atoms of the sulfonyl
group (observed also in TBZA), the 2-amino group is involved in
an intramolecular H-bond with chloride ion, while in TBZA (as
discussed above) it is connected to an imidazole nitrogen atom of
a neighbor molecule (Table 3). The crystal structures of both
complexes are stabilized by a network of nonconventional H-
bonds which involve tosyl or benzimidazole carbon atoms as
proton donors with sulfonyl or chloride atoms as proton acceptors
(Table 3). Moreover, molecules in the Cu(II) complex pack,
forming a channel parallel to the crystallographic a axis, where
butane molecules are linked by H-bonds with chloride ions
bonded to the metal centers.
The FTIR spectra show a characteristic spectroscopic pattern
for each complex. However, a qualitative similarity can be seen in
the spectra of the Co(II) and Zn(II) complexes (Figure 3). The
great similarity of the infrared spectra, even at low frequencies,
leads us to infer that the Co(II) and Zn(II) complexes are
isostructural. The three complexes show that the group amino is
not involved in the coordination of the central ion, since 	NH
modes do no shift significantly with respect to the free
sulfonamide. However, a decrease of approximately 25 cm1
with respect to the free sulfonamide 	NH evidences a slight
weakening of the bond NH by interaction with chloride ions
(Table 4). The bands observed at 1640, 1540, and 1420 cm1
show complexation through azolic nitrogen, because they are
assigned to the 	C-N stretching modes, and are weakened in the
three complexes with respect to the values observed in the free
sulfonamide.
The thermal behavior of the complexes shows similar patterns
of decomposition. Figure 4(b–d) presents the thermal diagrams of
Co(II), Cu(II), and Zn(II) complexes, respectively.
Unlike the free sulfonamide that melts and then decomposes,
the complexes melt and decompose immediately. The three
complexes underwent a first endothermic process followed by an
exothermic one with loss of mass, which in the case of the
complex of Co(II) was 3.24%, (c.a. 4.25%, on set 148.42 C), for
Cu(II) complex was 4.94% (c.a. 4.14%, on set 259.82 C), and for
Zn(II) complex was 5.45% (c.a. 4.22%, on set 263.42 C). This
mass loss is assigned to the loss of the methyl of the tosyl group,
as it is the case with the sulfonamide. Then, a series of exothermic
and endothermic processes followed, in which the loss was
between 20 and 30% of the mass. It can be estimated that two
chlorides and sulfonyl groups were lost, representing, in the case
of the Co(II) complex, a loss of mass of 28.08% (ca. 29%, on set
250.18 C), in the case of the Cu(II) complex, 29.78% (ca. 29%,
on set 285.06 C), and in the case of the Zn(II) complex, 29.17%
(ca. 29%, on set 334.12 C). Two exothermic processes followed
from 480 C approximately, where the 58.28% (on set 480.16 C)
of the mass for the Co(II) complex, the 55.43% (on set 478.00 C)
of mass for the Cu(II) complex, and the 56.48% (on set 475.94 C)
of the mass for the Zn(II) complex were lost. This similarity in theT
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thermal behaviors indicates that the structure of the complexes is
similar, according to their crystal structures. This agreement leads
us to further infer that the Zn(II) complex can be isostructural to
Co (II) complex.
The residues remaining after calcination were measured using
XRD powder. The diffractograms obtained are in agreement with
the corresponding Co(II) (PDF# 00–009-0402), Cu(II) (PDF# 00–
005-0661), and Zn(II) (PDF# 00–005-0664) oxides.
Figure 4. (a) DTA–TGA graphics of TBZA; (b) DSC–TGA graphics of Co(II) complex; (c) DSC–TGA graphics of Cu(II) complex; (d) DSC–TGA
graphics of Zn(II) complex.
Figure 5. Proposed decomposition of TBZA..
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When measuring Zn(II) and Co(II) complexes, the XRD
powder showed that the crystalline phases were equivalents (but
not coincident). As there are coincidences in the crystallographic
planes, we may say that both phases are isostructural (Figure 8).
This fact confirms what has been inferred in the analysis of FTIR
spectra, elemental analysis, and thermal diagrams.
DFT calculations
Geometry
Full geometry optimizations of the single crystal XRD coordin-
ates (complexes TBZA-Cu(II) and TBZA-Co(II)) and the
proposed coordinates for the TBZA-Zn(II) complex assumed
from it XRPD spectra were carried out. The B3LYP functional
with the 6–311G + (2d,p) and SDD(ECP) basis sets was selected
for the TBZA and M(II) moieties, respectively. Geometry
optimizations were carried out by global energy minimization
without any structural constraint followed by frequencies analysis
Figure 7. Coordination of the TBZA ligand
around the Co(II) metal center, showing the
displacement ellipsoids at the 30% probabil-
ity level. The intra and intermolecular H-
bonds are shown in dashed line. Symmetry
operations are listed in Table 3.
Figure 6. Coordination of the TBZA ligand
around the Cu(II) metal center, showing the
displacement ellipsoids at the 30% probabil-
ity level. The intra and intermolecular H-
bonds are shown in dashed line. Symmetry
operations are listed in Table 3.
Figure 8. Powder XRD of Co(II) complex and Zn(II) complex.
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to characterize the final structures as global minimum. No
negative frequencies were found.
In order to obtain a feeling for the overall discrepancies
between the experimental and the optimized coordinates, and to
assess the influence of the selected DFT functional and basis set,
we have measured the overall RMSD between the energy
minimized structures with respect to the corresponding experi-
ment coordinates. The minimized structures showed RMSD of
0.605, 0.935, and 0.673 angstroms for the TBZA-Zn(II), TBZA-
Cu(II), and TBZA-Co(II) complexes, respectively. Thus, the final
DFT geometries correspond closely with the experimental data.
We assumed that no significant structural drift from its starting
crystallographic coordinates occurred. According to these results,
the conformations obtained by DFT geometry optimization were
taken to perform the subsequent QTAIM analysis.
QTAIM analysis
The nature and strength of the metal–ligand bond for the TBZA-
M(II) were investigated in the light of the QTAIM theory32,33,
using the B3LYP/6–311 + G(2d,p):Def2-QZVP wave function.
Selected topological parameters are listed in Table 5. The number
of critical points (CP) found for all of the analyzed systems are in
agreement with the Poincare–Hopf rule32, indicating not only that
the complexes are well stabilized in terms of electron density
distribution but also pointing out that the free TBZA can be
stabilized by M(II) complexation, at least for Co(II), Cu(II), and
Zn(II) ions.
N–M(II) (N11–M(II), N21–M(II)) interaction
From Table 5, it can be seen that the values of  are in a range
from 0.0783 to 0.0849 au, and the values of r2 are positive,
whereas the number of electron pairs shared between the two
atomic basins are d(A,B)51. These results indicate a close-shell
interaction at the BCP55. Concordantly, the amount of kinetic
energy per electron is large, G/41. In fact, the N–M(II)
interaction might be classified as dative bonding (V50, and
H50) although some amount of covalence might be present,
playing, sometimes, a fundamental role.
Cl–M(II) (Cl1–M(II), Cl2–M(II)) interaction
The values of  are in a range from 0.0642 to 0.0657 au, with
positive values of r2. The number of electron pairs shared by
two atomic basins is d(A,B)41, with an amount of kinetic energy
per electron (G/) lower than the unity (Table 5). These results
indicate a shared-shell interaction at the Cl–M(II) BCP, and might
be classified as covalent bonding (V50, and H50)55.
The topological results reinforce the fact that the TBZA
complexes are better stabilized at the N–M(II) BCP by close-shell
dative bonding with a slightly covalent character.
Biological assays
Antifungal activity
The antifungal activity of TBZA and its complexes was evaluated
against different strains of yeasts of clinical relevance, such as C.
albicans (DMic 972576), C. krusei (DMic 951705), C. glabrata
(DMic 982882), C. tropicalis (DMic 982884), C. dubliniensis
(DMic 93695), C. guilliermondii (DMic 021150), C. neoformans
(ATCC 24067), and C. gattii (ATCC MYA-4561). The results
obtained with the studied compounds are presented in Table 6.
Regarding the antifungal activity, these compounds demon-
strated to be effective against the assayed yeasts. The maximum
zones of inhibition for TBZA, its Co(II), Cu(II), and Zn(II)
Table 5. Topological properties at the BCP for selected binuclear interactions.
BCPa Re
b,j c,k r2d,k Ge,k G/f,k Vg,k Hh,k d(A,B)i,k
NaZn(II) 2.053 0.0783 0.2972 0.0947 1.2094 –0.1152 –0.0204 0.8574
NbZn(II) 2.053 0.0784 0.2975 0.0949 1.2104 –0.1154 –0.0205 0.8589
ClaZn(II) 2.309 0.0657 0.1726 0.0608 0.9254 –0.0785 –0.0177 1.1112
ClbZn(II) 2.308 0.0656 0.1725 0.0608 0.9268 –0.0784 –0.0176 1.1110
NaCu(II) 2.017 0.0848 0.3282 0.1075 1.2676 –0.1329 –0.0254 0.9694
NbCu(II) 2.017 0.0849 0.3282 0.1075 1.2661 –0.1329 –0.0254 0.9689
ClaCu(II) 2.316 0.0650 0.1627 0.0587 0.9030 –0.0768 –0.0180 1.2344
ClbCu(II) 2.316 0.0650 0.1627 0.0587 0.9030 –0.0768 –0.0180 1.2345
NaCo(II) 2.038 0.0812 0.3576 0.1107 1.3633 –0.1320 –0.0213 0.9312
NbCo(II) 2.038 0.0812 0.3574 0.1107 1.3633 –0.1320 –0.0213 0.9311
ClaCo(II) 2.325 0.0642 0.1796 0.0629 0.9797 –0.0809 –0.0180 1.2028
ClbCo(II) 2.325 0.0642 0.1796 0.0629 0.9797 –0.0809 –0.0180 1.2029
aBCP involving M(II) ion; bdistance between nuclei; celectron density and dits Laplacian (r2); ekinetic electron energy; fkinetic energy per electron;
gpotential electron energy; htotal electron energy density (G + V); idelocalization index. jin A˚; kin a.u.
Table 6. Antifungal activity of TBZA and its complexes, voriconazole (VNZ), and fluconazole (FNZ).
Tested fungal strains aTBZA (83 mg)
aTBZA Co(II)
complex (5mg)
aTBZA Cu(II)
complex (5 mg)
aTBZA Zn(II)
complex (5mg) aVNZ (1 mg) aFNZ (25 mg)
Candida albicans 10 ± 3 12 ± 2 12 ± 2 17 ± 2 25 ± 4 20 ± 5
Candida krusei 10 ± 2 17 ± 2 14 ± 1 15 ± 3 23 ± 3 15 ± 3
Candida glabrata 13 ± 3 15 ± 1 12 ± 2 18 ± 2 24 ± 4 22 ± 3
Candida tropicalis 15 ± 2 12 ± 2 13 ± 2 20 ± 3 23 ± 6 22 ± 4
Candida dubliniensis 10 ± 2 14 ± 1 14 ± 2 14 ± 2 25 ± 5 20 ± 5
Candida guilliermondii 12 ± 1 12 ± 2 12 ± 2 22 ± 3 26 ± 4 22 ± 5
Cryptococcus neoformans 18 ± 3 20 ± 3 15 ± 1 22 ± 3 24 ± 5 20 ± 4
Cryptococcus gattii 13 ± 2 15 ± 1 15 ± 3 15 ± 2 25 ± 5 20 ± 5
All values represented in the table are average of results of three separately conducted experiments.
aZone of inhibition (mm), aX ± SD, mean of five measurements ± standard deviation.
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complexes were observed against Cryptococcus neoformans
(18 ± 3, 20 ± 3, 15 ± 1, and 22 ± 3 mm, respectively) compared
with the other yeasts investigated in the present study. Moreover,
several studies of antifungal activity using CoCl2, CuCl2, and
ZnCl2 commercial salts were performed against the same tested
yeasts. The results of these studies did not show zones of
inhibition (data not shown).
These results strongly suggest that the TBZA and its
complexes may possess a significant antifungal activity.
However, further studies should be performed to understand the
toxicity of the studied compounds before developing these novel
substances for clinical applications.
CA inhibition
Inhibition data with TBZA salts against various human (h) CAs,
hCA I, II, IV, VII, IX, and XII, and pathogenic beta and gamma
CAs, have been obtained. Acetazolamide, a well-known CAI, was
used as a standard drug for comparison (Table 7). As in other CAs
inhibition assays with sulfonamides and their metal complexes,
phenols, and thiophenols, the enzymes were incubated for 10–
15 min with test compounds to allowing the formation of the
enzyme-inhibitor adduct44–48,56–60. Working under similar condi-
tions, TBZA, Co(II), Cu(II), and Zn(II) complexes were found to
be poor inhibitors of both hCAs and microorganisms CAs in the
micromolar concentration range, although they exhibited a very
weak inhibitory power compared to AZA (Table 7). However, an
exception occurs with P. gingivalis CA g, where good inhibitory
action was observed (Table 8). These results show that the
interaction of the sulfonamide with the active site of the enzyme is
weaker (than it is for AZA), due to the fact that the TBZA is a
substituted sulfonamide and it does not allow the stabilization
adduct between the Zn (II) active site of the enzyme and TBZA or
its metal complexes. This is consistent with the X-ray crystal
structures, in which the deprotonated sulfonamide group appears
bound to the Zn(II) ion from the enzyme active site7,47,48.
In previous studies, it was found that, by inhibiting CAs from
bacterial or other pathogens, an inhibition in the growth of the
studied microorganisms occurred41,48,49. Table 8 shows the values
of enzyme inhibition for CAs in P. gingivalis (responsible for
periodontal pathogenicity) and Cryptococcus neoformans
(responsible for serious, systemic fungal diseases)1,7,8.
According to these values, the best results were obtained against
PgiCAgamma. Thus, the TBZA may be considered an interesting
candidate for possible application in designing antiinfective agent
with a novel mechanism of action against P. gingivalis.
Conclusions
This study reports the synthesis and characterization of a new
sulfonamide and its Co(II), Cu(II), and Zn(II) complexes. The
TBZA and Co(II) and Cu(II) complexes were structurally
characterized for the first time via X-ray crystallography.
The spectroscopy properties resulted in good agreement with
the X-Ray crystallographic results, and in the Zn(II) complex,
these studies suggest that it is isostructural with Co(II) complex.
The DFT geometries corresponded closely with the experi-
mental data and no significant structural drift from its crystallo-
graphic coordinates occurred. From the QTAM analysis, we can
rationalize that the N–M(II) interaction might be classified as
dative bonding with some amount of covalence, while the QTAIM
analysis of the Cl–M(II) interaction indicates a covalent bonding.
In addition, from the  and d(A,B) values, we may assume that
the TBZA–M(II) complexes become stabilized following the
delocalization index trend, Cu(II)&Co(II)4Zn(II).
The TBZA and its complex demonstrated that, in vitro, they
have a clear antifungal activity against the assayed yeasts.
However, TBZA and the Zn(II) complex showed a higher
inhibition than the other complexes.
All the compounds showed a lower CA inhibitory property
than AZA. However, TBZA presented the highest inhibitory
activity against hCA XII. The hCA II results for Cu(II) complex
suggest that the inhibitory activity is probably due to the metal ion
and not to the TBZA. The results of the enzymatic inhibition in C.
neoformans and P. gingivalis indicate that the CA inhibition is not
responsible for the growing yeast inhibition, but TBZA is an
effective inhibitor of the gamma CA of the P. gingivalis.
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